Skip to content
Screener

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$4.89M-102%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-$57.94M-37.0%
ALN
Alnylam PharmaceuticalsALNY
$164.49M+348%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$94.32M+12.9%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$120.85M-4.8%

Other financials

Income statement

See full
Revenue$2.3M-73.9%
Operating income-$73.8M-39.9%
EPS (diluted)-$0.34-9.7%

Balance sheet

See full
Cash & equivalents$368.0M+76.5%
Total debt$43.6M+101%
Total equity$453.5M+226%
Total assets$558.3M+121%

Cash flow

See full
Operating cash flow-$53.6M-16.5%
CapEx$884.0K+189%
Free cash flow-$54.5M-17.6%

Valuation

See full
Market cap$1.2B-6.8%
Enterprise value$877.58M-20.4%
P/S20.6×-16.6×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-68.3%
Debt / equity0.1×-0.1×
Current ratio10×+7.4×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324949
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income, net4,4472,2909,6575,216
Loss before income taxes(69,355)(50,469)(95,442)(97,347)
Income tax benefit
Net loss$(69,355)$(50,469)$(95,442)$(97,347)
Net loss per share attributable to ordinary shareholders—basic and diluted$(0.34)$(0.31)$(0.47)$(0.60)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders—basic and diluted204,008,712163,987,640202,098,901163,266,106
Other comprehensive loss:
Net loss$(69,355)$(50,469)$(95,442)$(97,347)

Item 1. Financial Statements

FAQ

What is Wave Life Sciences's net income?
Wave Life Sciences (WVE) reported net income of -$69.36M in Q2 2026.
How has Wave Life Sciences's net income changed year-over-year?
Wave Life Sciences's net income decreased by 37.4% year-over-year, from -$50.47M to -$69.36M.
What is the long-term trend for Wave Life Sciences's net income?
Over 3 years (2021 to 2025), Wave Life Sciences's net income has grown at a 18.7% compound annual growth rate (CAGR), from -$122.25M to -$204.38M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Wave Life Sciences's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude